Studies heart rhythm changes in people taking BTK inhibitors or venetoclax
Observes heart rhythm effects in adults with blood cancers taking BTK inhibitors or venetoclax.
Key facts
- Who runs it
- National Heart, Lung, and Blood Institute (NHLBI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- Status
- Recruiting
- People taking part
- 135 people, planned
- Started
- 1 Mar 2023
- Expected to end
- 8 Apr 2027
- Type of study
- Observational, 3 groups
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are taking, or plan to take, a BTK inhibitor (BTKi) or venetoclax. It watches how these drugs affect the heart.
- Age
- 18 years or older (up to 110 years)
- Sex
- All sexes can join.
- Earlier treatment
- Currently receiving, or planning to receive, a BTKi or venetoclax.
Main reasons for not taking part
- Acute heart condition, including heart attack or decompensated heart failure, within the past 3 months
- Pregnancy or breastfeeding
- Unable or unwilling to follow all study procedures for the whole study
- Unable or unwilling to understand and sign the written consent form
The registry criteria, word for word
Show all 8 criteriaShow less
Who cannot take part
- Pregnancy or lactation- use of BTK inhibitors is contraindicated in pregnant or nursing individuals
- Any acute cardiac condition including myocardial infarction or decompensated heart failure within the past 3 months
- An individual who meets any of the following criteria will be excluded from participation in this study:
Other criteria
- INCLUSION CRITERIA:; To be eligible to participate in this study, an individual must meet all of the following criteria:
- Currently receiving or planning to receive a BTKi or venetoclax
- Male or female, aged 18 or older
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability of subject to understand and the willingness to sign a written informed consent document
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: NIH Clinical Center Office of Patient Recruitment (OPR)Taking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.
Objective:
To identify and monitor the effects of BTKi on the heart.
Eligibility:
People aged 18 and older currently receiving or planning to receive BTKi or venetoclax.
Design:
Participants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit.
Participants will undergo multiple tests:
A physical exam, including collection of blood and saliva.
A test that measures heart activity via stickers placed on the chest.
A test that uses sound waves to capture images of the heart.
An exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises.
Stress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken.
Participants may wear a device to monitor their heart at home.
Participants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.
The 3 groups in the trial
- Cohort A
includes all patients prior to starting therapy with a BTKi
- Cohort B
includes all patients already on therapy with a BTKi
- Cohort C
includes all patients prior to starting therapy with venetoclax
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
- Plain-language title
- Studies heart rhythm changes in people taking BTK inhibitors or venetoclaxGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05724121, who can take part
- Record updated
- 29 October 2026